Smart Immune to Present ReSet-02 Phase I Preliminary Data and the Determination of the Recommended Dose at ASH 2024
November 5, 2024
Aurelie Bauquet, head of clinical development and Olivier Negre, chief scientific officer at Smart Immune have published in the journal “Innovations et Thérapeutiques en Oncologie”, issued by John Libbey Eurotext.
The article provides an overview of our ex vivo cell culture technology, from a scientific and clinical perspective, and its complementary applications in immuno-oncology.
For those who know the language of Molière, the article is available in open access here.